nodes	percent_of_prediction	percent_of_DWPC	metapath
Doxorubicin—NOS3—chronic obstructive pulmonary disease	0.269	0.509	CbGaD
Doxorubicin—NOS2—chronic obstructive pulmonary disease	0.259	0.491	CbGaD
Doxorubicin—CYP2D6—Arformoterol—chronic obstructive pulmonary disease	0.0171	0.147	CbGbCtD
Doxorubicin—CYP2D6—Formoterol—chronic obstructive pulmonary disease	0.0171	0.147	CbGbCtD
Doxorubicin—CYP2D6—Tiotropium—chronic obstructive pulmonary disease	0.0153	0.131	CbGbCtD
Doxorubicin—CYP3A4—Salbutamol—chronic obstructive pulmonary disease	0.0144	0.124	CbGbCtD
Doxorubicin—CYP3A4—Tiotropium—chronic obstructive pulmonary disease	0.0097	0.0835	CbGbCtD
Doxorubicin—CYP3A4—Aminophylline—chronic obstructive pulmonary disease	0.00925	0.0797	CbGbCtD
Doxorubicin—CYP3A4—Montelukast—chronic obstructive pulmonary disease	0.00825	0.071	CbGbCtD
Doxorubicin—ABCB1—Prednisolone—chronic obstructive pulmonary disease	0.00808	0.0695	CbGbCtD
Doxorubicin—ABCB1—Prednisone—chronic obstructive pulmonary disease	0.00763	0.0657	CbGbCtD
Doxorubicin—NOS3—pulmonary artery—chronic obstructive pulmonary disease	0.00601	0.0785	CbGeAlD
Doxorubicin—CYP3A4—Prednisolone—chronic obstructive pulmonary disease	0.00484	0.0417	CbGbCtD
Doxorubicin—CYP3A4—Prednisone—chronic obstructive pulmonary disease	0.00457	0.0393	CbGbCtD
Doxorubicin—CBR3—bronchus—chronic obstructive pulmonary disease	0.00187	0.0244	CbGeAlD
Doxorubicin—AKR1A1—respiratory system—chronic obstructive pulmonary disease	0.00176	0.0229	CbGeAlD
Doxorubicin—CBR3—trachea—chronic obstructive pulmonary disease	0.00168	0.0219	CbGeAlD
Doxorubicin—AKR1A1—bronchus—chronic obstructive pulmonary disease	0.00144	0.0189	CbGeAlD
Doxorubicin—AKR1A1—smooth muscle tissue—chronic obstructive pulmonary disease	0.00141	0.0185	CbGeAlD
Doxorubicin—NDUFS7—connective tissue—chronic obstructive pulmonary disease	0.0014	0.0183	CbGeAlD
Doxorubicin—NOS1—respiratory system—chronic obstructive pulmonary disease	0.00133	0.0174	CbGeAlD
Doxorubicin—NDUFS2—respiratory system—chronic obstructive pulmonary disease	0.00132	0.0173	CbGeAlD
Doxorubicin—NDUFS7—bronchus—chronic obstructive pulmonary disease	0.00131	0.0171	CbGeAlD
Doxorubicin—NDUFS3—respiratory system—chronic obstructive pulmonary disease	0.00131	0.0171	CbGeAlD
Doxorubicin—AKR1A1—trachea—chronic obstructive pulmonary disease	0.0013	0.0169	CbGeAlD
Doxorubicin—ABCB8—lung—chronic obstructive pulmonary disease	0.00125	0.0164	CbGeAlD
Doxorubicin—CBR3—lung—chronic obstructive pulmonary disease	0.00121	0.0158	CbGeAlD
Doxorubicin—NDUFS2—connective tissue—chronic obstructive pulmonary disease	0.00116	0.0152	CbGeAlD
Doxorubicin—NDUFS3—connective tissue—chronic obstructive pulmonary disease	0.00115	0.015	CbGeAlD
Doxorubicin—YWHAG—respiratory system—chronic obstructive pulmonary disease	0.00114	0.0149	CbGeAlD
Doxorubicin—NDUFS2—bronchus—chronic obstructive pulmonary disease	0.00109	0.0142	CbGeAlD
Doxorubicin—NDUFS3—bronchus—chronic obstructive pulmonary disease	0.00107	0.014	CbGeAlD
Doxorubicin—NOS1—smooth muscle tissue—chronic obstructive pulmonary disease	0.00107	0.014	CbGeAlD
Doxorubicin—NDUFS2—smooth muscle tissue—chronic obstructive pulmonary disease	0.00106	0.0139	CbGeAlD
Doxorubicin—ABCC6—connective tissue—chronic obstructive pulmonary disease	0.00106	0.0139	CbGeAlD
Doxorubicin—NDUFS3—smooth muscle tissue—chronic obstructive pulmonary disease	0.00105	0.0137	CbGeAlD
Doxorubicin—RALBP1—respiratory system—chronic obstructive pulmonary disease	0.00103	0.0134	CbGeAlD
Doxorubicin—DHCR7—bronchus—chronic obstructive pulmonary disease	0.00102	0.0133	CbGeAlD
Doxorubicin—NOS3—respiratory system—chronic obstructive pulmonary disease	0.00101	0.0132	CbGeAlD
Doxorubicin—YWHAG—connective tissue—chronic obstructive pulmonary disease	0.001	0.0131	CbGeAlD
Doxorubicin—NDUFS2—trachea—chronic obstructive pulmonary disease	0.000977	0.0128	CbGeAlD
Doxorubicin—NDUFS3—trachea—chronic obstructive pulmonary disease	0.000965	0.0126	CbGeAlD
Doxorubicin—CBR1—respiratory system—chronic obstructive pulmonary disease	0.00096	0.0125	CbGeAlD
Doxorubicin—YWHAG—bronchus—chronic obstructive pulmonary disease	0.000937	0.0122	CbGeAlD
Doxorubicin—AKR1A1—lung—chronic obstructive pulmonary disease	0.000932	0.0122	CbGeAlD
Doxorubicin—DHCR7—trachea—chronic obstructive pulmonary disease	0.000917	0.012	CbGeAlD
Doxorubicin—YWHAG—smooth muscle tissue—chronic obstructive pulmonary disease	0.000917	0.012	CbGeAlD
Doxorubicin—NOS3—connective tissue—chronic obstructive pulmonary disease	0.00089	0.0116	CbGeAlD
Doxorubicin—POR—respiratory system—chronic obstructive pulmonary disease	0.000866	0.0113	CbGeAlD
Doxorubicin—NDUFS7—lung—chronic obstructive pulmonary disease	0.000847	0.0111	CbGeAlD
Doxorubicin—RALBP1—bronchus—chronic obstructive pulmonary disease	0.000846	0.011	CbGeAlD
Doxorubicin—YWHAG—trachea—chronic obstructive pulmonary disease	0.000841	0.011	CbGeAlD
Doxorubicin—RALBP1—smooth muscle tissue—chronic obstructive pulmonary disease	0.000828	0.0108	CbGeAlD
Doxorubicin—NOS3—smooth muscle tissue—chronic obstructive pulmonary disease	0.000815	0.0106	CbGeAlD
Doxorubicin—CBR1—bronchus—chronic obstructive pulmonary disease	0.00079	0.0103	CbGeAlD
Doxorubicin—AURKA—lung—chronic obstructive pulmonary disease	0.000788	0.0103	CbGeAlD
Doxorubicin—AKR1C3—bronchus—chronic obstructive pulmonary disease	0.00078	0.0102	CbGeAlD
Doxorubicin—NQO1—respiratory system—chronic obstructive pulmonary disease	0.000769	0.01	CbGeAlD
Doxorubicin—AKR1C3—smooth muscle tissue—chronic obstructive pulmonary disease	0.000763	0.00997	CbGeAlD
Doxorubicin—RALBP1—trachea—chronic obstructive pulmonary disease	0.00076	0.00992	CbGeAlD
Doxorubicin—NOS3—trachea—chronic obstructive pulmonary disease	0.000748	0.00976	CbGeAlD
Doxorubicin—Daunorubicin—CYP1A1—chronic obstructive pulmonary disease	0.000722	0.509	CrCbGaD
Doxorubicin—POR—bronchus—chronic obstructive pulmonary disease	0.000712	0.0093	CbGeAlD
Doxorubicin—CBR1—trachea—chronic obstructive pulmonary disease	0.000709	0.00926	CbGeAlD
Doxorubicin—NOS1—lung—chronic obstructive pulmonary disease	0.000706	0.00922	CbGeAlD
Doxorubicin—NDUFS2—lung—chronic obstructive pulmonary disease	0.000702	0.00917	CbGeAlD
Doxorubicin—AKR1C3—trachea—chronic obstructive pulmonary disease	0.000701	0.00915	CbGeAlD
Doxorubicin—Daunorubicin—CYP1A2—chronic obstructive pulmonary disease	0.000696	0.491	CrCbGaD
Doxorubicin—NDUFS3—lung—chronic obstructive pulmonary disease	0.000693	0.00905	CbGeAlD
Doxorubicin—ABCC3—respiratory system—chronic obstructive pulmonary disease	0.00069	0.00901	CbGeAlD
Doxorubicin—NQO1—connective tissue—chronic obstructive pulmonary disease	0.000677	0.00884	CbGeAlD
Doxorubicin—TOP2A—bronchus—chronic obstructive pulmonary disease	0.000664	0.00867	CbGeAlD
Doxorubicin—DHCR7—lung—chronic obstructive pulmonary disease	0.000659	0.0086	CbGeAlD
Doxorubicin—ABCC6—lung—chronic obstructive pulmonary disease	0.000642	0.00838	CbGeAlD
Doxorubicin—POR—trachea—chronic obstructive pulmonary disease	0.00064	0.00835	CbGeAlD
Doxorubicin—NQO1—bronchus—chronic obstructive pulmonary disease	0.000633	0.00826	CbGeAlD
Doxorubicin—NQO1—smooth muscle tissue—chronic obstructive pulmonary disease	0.000619	0.00809	CbGeAlD
Doxorubicin—YWHAG—lung—chronic obstructive pulmonary disease	0.000605	0.00789	CbGeAlD
Doxorubicin—NQO1—trachea—chronic obstructive pulmonary disease	0.000568	0.00742	CbGeAlD
Doxorubicin—ABCC10—bronchus—chronic obstructive pulmonary disease	0.000565	0.00738	CbGeAlD
Doxorubicin—RALBP1—lung—chronic obstructive pulmonary disease	0.000546	0.00713	CbGeAlD
Doxorubicin—CYP1B1—respiratory system—chronic obstructive pulmonary disease	0.00054	0.00705	CbGeAlD
Doxorubicin—NOS3—lung—chronic obstructive pulmonary disease	0.000537	0.00701	CbGeAlD
Doxorubicin—CBR1—lung—chronic obstructive pulmonary disease	0.00051	0.00665	CbGeAlD
Doxorubicin—ABCC10—trachea—chronic obstructive pulmonary disease	0.000508	0.00663	CbGeAlD
Doxorubicin—AKR1C3—lung—chronic obstructive pulmonary disease	0.000503	0.00657	CbGeAlD
Doxorubicin—TOP2A—Salmeterol—Salbutamol—chronic obstructive pulmonary disease	0.000493	0.189	CbGdCrCtD
Doxorubicin—CYP1B1—connective tissue—chronic obstructive pulmonary disease	0.000475	0.00621	CbGeAlD
Doxorubicin—POR—lung—chronic obstructive pulmonary disease	0.00046	0.006	CbGeAlD
Doxorubicin—CYP1B1—smooth muscle tissue—chronic obstructive pulmonary disease	0.000435	0.00568	CbGeAlD
Doxorubicin—TOP2A—lung—chronic obstructive pulmonary disease	0.000428	0.00559	CbGeAlD
Doxorubicin—NQO1—lung—chronic obstructive pulmonary disease	0.000408	0.00533	CbGeAlD
Doxorubicin—ABCC1—bronchus—chronic obstructive pulmonary disease	0.0004	0.00522	CbGeAlD
Doxorubicin—CYP2B6—respiratory system—chronic obstructive pulmonary disease	0.000371	0.00484	CbGeAlD
Doxorubicin—ABCC3—lung—chronic obstructive pulmonary disease	0.000367	0.00479	CbGeAlD
Doxorubicin—ABCC10—lung—chronic obstructive pulmonary disease	0.000365	0.00476	CbGeAlD
Doxorubicin—ABCC1—trachea—chronic obstructive pulmonary disease	0.000359	0.00469	CbGeAlD
Doxorubicin—CBR3—Fluorometholone—Prednisone—chronic obstructive pulmonary disease	0.000334	0.128	CbGdCrCtD
Doxorubicin—CBR3—Fluorometholone—Prednisolone—chronic obstructive pulmonary disease	0.000326	0.125	CbGdCrCtD
Doxorubicin—CYP2B6—bronchus—chronic obstructive pulmonary disease	0.000305	0.00399	CbGeAlD
Doxorubicin—CYP1B1—lung—chronic obstructive pulmonary disease	0.000287	0.00374	CbGeAlD
Doxorubicin—CBR3—Triamcinolone—Prednisone—chronic obstructive pulmonary disease	0.000276	0.106	CbGdCrCtD
Doxorubicin—CBR3—Triamcinolone—Prednisolone—chronic obstructive pulmonary disease	0.00027	0.104	CbGdCrCtD
Doxorubicin—ABCC1—lung—chronic obstructive pulmonary disease	0.000258	0.00337	CbGeAlD
Doxorubicin—CBR3—Fluocinolone Acetonide—Prednisolone—chronic obstructive pulmonary disease	0.000248	0.0951	CbGdCrCtD
Doxorubicin—ABCG2—lung—chronic obstructive pulmonary disease	0.000214	0.00279	CbGeAlD
Doxorubicin—ABCB1—respiratory system—chronic obstructive pulmonary disease	0.000198	0.00259	CbGeAlD
Doxorubicin—CYP2B6—lung—chronic obstructive pulmonary disease	0.000197	0.00257	CbGeAlD
Doxorubicin—ABCB1—trachea—chronic obstructive pulmonary disease	0.000147	0.00191	CbGeAlD
Doxorubicin—CBR3—Betamethasone—Prednisone—chronic obstructive pulmonary disease	0.000137	0.0524	CbGdCrCtD
Doxorubicin—CBR3—Dexamethasone—Prednisone—chronic obstructive pulmonary disease	0.000137	0.0524	CbGdCrCtD
Doxorubicin—CBR3—Betamethasone—Prednisolone—chronic obstructive pulmonary disease	0.000133	0.0512	CbGdCrCtD
Doxorubicin—CBR3—Dexamethasone—Prednisolone—chronic obstructive pulmonary disease	0.000133	0.0512	CbGdCrCtD
Doxorubicin—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.000106	0.000675	CcSEcCtD
Doxorubicin—ABCB1—lung—chronic obstructive pulmonary disease	0.000105	0.00137	CbGeAlD
Doxorubicin—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.000105	0.000672	CcSEcCtD
Doxorubicin—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.000105	0.00067	CcSEcCtD
Doxorubicin—Thrombocytopenia—Montelukast—chronic obstructive pulmonary disease	0.000105	0.000669	CcSEcCtD
Doxorubicin—Abdominal distension—Prednisolone—chronic obstructive pulmonary disease	0.000105	0.000669	CcSEcCtD
Doxorubicin—Sepsis—Prednisone—chronic obstructive pulmonary disease	0.000105	0.000668	CcSEcCtD
Doxorubicin—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.000104	0.000664	CcSEcCtD
Doxorubicin—Oedema—Salbutamol—chronic obstructive pulmonary disease	0.000103	0.000659	CcSEcCtD
Doxorubicin—Anaphylactic shock—Salbutamol—chronic obstructive pulmonary disease	0.000103	0.000659	CcSEcCtD
Doxorubicin—Infection—Salbutamol—chronic obstructive pulmonary disease	0.000102	0.000654	CcSEcCtD
Doxorubicin—Hypotension—Arformoterol—chronic obstructive pulmonary disease	0.000102	0.000652	CcSEcCtD
Doxorubicin—Hypotension—Formoterol—chronic obstructive pulmonary disease	0.000102	0.000652	CcSEcCtD
Doxorubicin—Pancreatitis—Prednisolone—chronic obstructive pulmonary disease	0.000102	0.000651	CcSEcCtD
Doxorubicin—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.000102	0.000649	CcSEcCtD
Doxorubicin—Shock—Salbutamol—chronic obstructive pulmonary disease	0.000101	0.000648	CcSEcCtD
Doxorubicin—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000101	0.000646	CcSEcCtD
Doxorubicin—Thrombophlebitis—Prednisone—chronic obstructive pulmonary disease	0.000101	0.000645	CcSEcCtD
Doxorubicin—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	0.000101	0.000643	CcSEcCtD
Doxorubicin—Diabetes mellitus—Prednisone—chronic obstructive pulmonary disease	0.000101	0.000642	CcSEcCtD
Doxorubicin—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.0001	0.00064	CcSEcCtD
Doxorubicin—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	9.97e-05	0.000637	CcSEcCtD
Doxorubicin—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	9.97e-05	0.000637	CcSEcCtD
Doxorubicin—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	9.95e-05	0.000636	CcSEcCtD
Doxorubicin—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	9.95e-05	0.000636	CcSEcCtD
Doxorubicin—Insomnia—Formoterol—chronic obstructive pulmonary disease	9.88e-05	0.000631	CcSEcCtD
Doxorubicin—Insomnia—Arformoterol—chronic obstructive pulmonary disease	9.88e-05	0.000631	CcSEcCtD
Doxorubicin—Anorexia—Salbutamol—chronic obstructive pulmonary disease	9.83e-05	0.000628	CcSEcCtD
Doxorubicin—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	9.82e-05	0.000627	CcSEcCtD
Doxorubicin—Vascular purpura—Prednisone—chronic obstructive pulmonary disease	9.77e-05	0.000624	CcSEcCtD
Doxorubicin—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	9.74e-05	0.000623	CcSEcCtD
Doxorubicin—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	9.74e-05	0.000622	CcSEcCtD
Doxorubicin—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	9.74e-05	0.000622	CcSEcCtD
Doxorubicin—Somnolence—Formoterol—chronic obstructive pulmonary disease	9.71e-05	0.00062	CcSEcCtD
Doxorubicin—Somnolence—Arformoterol—chronic obstructive pulmonary disease	9.71e-05	0.00062	CcSEcCtD
Doxorubicin—Insomnia—Montelukast—chronic obstructive pulmonary disease	9.67e-05	0.000618	CcSEcCtD
Doxorubicin—Cardiac failure congestive—Prednisone—chronic obstructive pulmonary disease	9.64e-05	0.000616	CcSEcCtD
Doxorubicin—Hypotension—Salbutamol—chronic obstructive pulmonary disease	9.63e-05	0.000616	CcSEcCtD
Doxorubicin—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	9.61e-05	0.000614	CcSEcCtD
Doxorubicin—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	9.61e-05	0.000614	CcSEcCtD
Doxorubicin—Paraesthesia—Montelukast—chronic obstructive pulmonary disease	9.6e-05	0.000614	CcSEcCtD
Doxorubicin—Pruritus—Tiotropium—chronic obstructive pulmonary disease	9.57e-05	0.000612	CcSEcCtD
Doxorubicin—Somnolence—Montelukast—chronic obstructive pulmonary disease	9.51e-05	0.000608	CcSEcCtD
Doxorubicin—Dizziness—Aminophylline—chronic obstructive pulmonary disease	9.49e-05	0.000606	CcSEcCtD
Doxorubicin—Weight increased—Prednisolone—chronic obstructive pulmonary disease	9.46e-05	0.000605	CcSEcCtD
Doxorubicin—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	9.43e-05	0.000602	CcSEcCtD
Doxorubicin—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	9.43e-05	0.000602	CcSEcCtD
Doxorubicin—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	9.42e-05	0.000602	CcSEcCtD
Doxorubicin—Fatigue—Arformoterol—chronic obstructive pulmonary disease	9.41e-05	0.000602	CcSEcCtD
Doxorubicin—Fatigue—Formoterol—chronic obstructive pulmonary disease	9.41e-05	0.000602	CcSEcCtD
Doxorubicin—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	9.39e-05	0.0006	CcSEcCtD
Doxorubicin—Constipation—Formoterol—chronic obstructive pulmonary disease	9.34e-05	0.000597	CcSEcCtD
Doxorubicin—Constipation—Arformoterol—chronic obstructive pulmonary disease	9.34e-05	0.000597	CcSEcCtD
Doxorubicin—Pain—Arformoterol—chronic obstructive pulmonary disease	9.34e-05	0.000597	CcSEcCtD
Doxorubicin—Pain—Formoterol—chronic obstructive pulmonary disease	9.34e-05	0.000597	CcSEcCtD
Doxorubicin—Insomnia—Salbutamol—chronic obstructive pulmonary disease	9.33e-05	0.000596	CcSEcCtD
Doxorubicin—Increased appetite—Prednisone—chronic obstructive pulmonary disease	9.31e-05	0.000595	CcSEcCtD
Doxorubicin—Paraesthesia—Salbutamol—chronic obstructive pulmonary disease	9.26e-05	0.000592	CcSEcCtD
Doxorubicin—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	9.23e-05	0.00059	CcSEcCtD
Doxorubicin—Fatigue—Montelukast—chronic obstructive pulmonary disease	9.22e-05	0.000589	CcSEcCtD
Doxorubicin—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	9.19e-05	0.000587	CcSEcCtD
Doxorubicin—Somnolence—Salbutamol—chronic obstructive pulmonary disease	9.17e-05	0.000586	CcSEcCtD
Doxorubicin—Pain—Montelukast—chronic obstructive pulmonary disease	9.15e-05	0.000584	CcSEcCtD
Doxorubicin—Vomiting—Aminophylline—chronic obstructive pulmonary disease	9.12e-05	0.000583	CcSEcCtD
Doxorubicin—Neuropathy peripheral—Prednisolone—chronic obstructive pulmonary disease	9.09e-05	0.000581	CcSEcCtD
Doxorubicin—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	9.08e-05	0.00058	CcSEcCtD
Doxorubicin—Purpura—Prednisone—chronic obstructive pulmonary disease	9.07e-05	0.00058	CcSEcCtD
Doxorubicin—Rash—Aminophylline—chronic obstructive pulmonary disease	9.05e-05	0.000578	CcSEcCtD
Doxorubicin—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	9.04e-05	0.000577	CcSEcCtD
Doxorubicin—Conjunctivitis—Prednisolone—chronic obstructive pulmonary disease	9.01e-05	0.000576	CcSEcCtD
Doxorubicin—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	9e-05	0.000575	CcSEcCtD
Doxorubicin—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	9e-05	0.000575	CcSEcCtD
Doxorubicin—Headache—Aminophylline—chronic obstructive pulmonary disease	8.99e-05	0.000574	CcSEcCtD
Doxorubicin—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	8.96e-05	0.000573	CcSEcCtD
Doxorubicin—Cardiac failure—Prednisone—chronic obstructive pulmonary disease	8.96e-05	0.000572	CcSEcCtD
Doxorubicin—Dizziness—Tiotropium—chronic obstructive pulmonary disease	8.95e-05	0.000572	CcSEcCtD
Doxorubicin—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	8.93e-05	0.000571	CcSEcCtD
Doxorubicin—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	8.93e-05	0.000571	CcSEcCtD
Doxorubicin—Lethargy—Prednisone—chronic obstructive pulmonary disease	8.92e-05	0.00057	CcSEcCtD
Doxorubicin—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	8.9e-05	0.000569	CcSEcCtD
Doxorubicin—Fatigue—Salbutamol—chronic obstructive pulmonary disease	8.89e-05	0.000568	CcSEcCtD
Doxorubicin—Constipation—Salbutamol—chronic obstructive pulmonary disease	8.82e-05	0.000563	CcSEcCtD
Doxorubicin—Pain—Salbutamol—chronic obstructive pulmonary disease	8.82e-05	0.000563	CcSEcCtD
Doxorubicin—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	8.75e-05	0.000559	CcSEcCtD
Doxorubicin—Osteoarthritis—Prednisone—chronic obstructive pulmonary disease	8.74e-05	0.000559	CcSEcCtD
Doxorubicin—Gastrointestinal haemorrhage—Prednisone—chronic obstructive pulmonary disease	8.74e-05	0.000559	CcSEcCtD
Doxorubicin—Urticaria—Arformoterol—chronic obstructive pulmonary disease	8.68e-05	0.000554	CcSEcCtD
Doxorubicin—Urticaria—Formoterol—chronic obstructive pulmonary disease	8.68e-05	0.000554	CcSEcCtD
Doxorubicin—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	8.63e-05	0.000552	CcSEcCtD
Doxorubicin—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	8.63e-05	0.000552	CcSEcCtD
Doxorubicin—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	8.63e-05	0.000552	CcSEcCtD
Doxorubicin—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	8.63e-05	0.000552	CcSEcCtD
Doxorubicin—Affect lability—Prednisone—chronic obstructive pulmonary disease	8.61e-05	0.00055	CcSEcCtD
Doxorubicin—Vomiting—Tiotropium—chronic obstructive pulmonary disease	8.6e-05	0.00055	CcSEcCtD
Doxorubicin—Rash—Tiotropium—chronic obstructive pulmonary disease	8.53e-05	0.000545	CcSEcCtD
Doxorubicin—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	8.52e-05	0.000545	CcSEcCtD
Doxorubicin—Nausea—Aminophylline—chronic obstructive pulmonary disease	8.52e-05	0.000545	CcSEcCtD
Doxorubicin—Urticaria—Montelukast—chronic obstructive pulmonary disease	8.5e-05	0.000543	CcSEcCtD
Doxorubicin—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	8.5e-05	0.000543	CcSEcCtD
Doxorubicin—Headache—Tiotropium—chronic obstructive pulmonary disease	8.48e-05	0.000542	CcSEcCtD
Doxorubicin—Bradycardia—Prednisolone—chronic obstructive pulmonary disease	8.47e-05	0.000541	CcSEcCtD
Doxorubicin—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	8.46e-05	0.00054	CcSEcCtD
Doxorubicin—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	8.46e-05	0.00054	CcSEcCtD
Doxorubicin—Face oedema—Prednisone—chronic obstructive pulmonary disease	8.44e-05	0.000539	CcSEcCtD
Doxorubicin—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	8.43e-05	0.000539	CcSEcCtD
Doxorubicin—Haemoglobin—Prednisolone—chronic obstructive pulmonary disease	8.37e-05	0.000535	CcSEcCtD
Doxorubicin—Haemorrhage—Prednisolone—chronic obstructive pulmonary disease	8.32e-05	0.000532	CcSEcCtD
Doxorubicin—Cardiac arrest—Prednisone—chronic obstructive pulmonary disease	8.31e-05	0.000531	CcSEcCtD
Doxorubicin—Mood swings—Prednisone—chronic obstructive pulmonary disease	8.28e-05	0.000529	CcSEcCtD
Doxorubicin—Urticaria—Salbutamol—chronic obstructive pulmonary disease	8.19e-05	0.000523	CcSEcCtD
Doxorubicin—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	8.15e-05	0.000521	CcSEcCtD
Doxorubicin—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	8.15e-05	0.000521	CcSEcCtD
Doxorubicin—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	8.05e-05	0.000514	CcSEcCtD
Doxorubicin—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	8.05e-05	0.000514	CcSEcCtD
Doxorubicin—Nausea—Tiotropium—chronic obstructive pulmonary disease	8.04e-05	0.000514	CcSEcCtD
Doxorubicin—Visual impairment—Prednisolone—chronic obstructive pulmonary disease	8.02e-05	0.000513	CcSEcCtD
Doxorubicin—Dry skin—Prednisone—chronic obstructive pulmonary disease	8.01e-05	0.000512	CcSEcCtD
Doxorubicin—Hypokalaemia—Prednisone—chronic obstructive pulmonary disease	7.96e-05	0.000508	CcSEcCtD
Doxorubicin—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	7.88e-05	0.000503	CcSEcCtD
Doxorubicin—Asthenia—Formoterol—chronic obstructive pulmonary disease	7.83e-05	0.000501	CcSEcCtD
Doxorubicin—Asthenia—Arformoterol—chronic obstructive pulmonary disease	7.83e-05	0.000501	CcSEcCtD
Doxorubicin—Pruritus—Arformoterol—chronic obstructive pulmonary disease	7.73e-05	0.000494	CcSEcCtD
Doxorubicin—Pruritus—Formoterol—chronic obstructive pulmonary disease	7.73e-05	0.000494	CcSEcCtD
Doxorubicin—Muscular weakness—Prednisone—chronic obstructive pulmonary disease	7.71e-05	0.000493	CcSEcCtD
Doxorubicin—Alanine aminotransferase increased—Prednisone—chronic obstructive pulmonary disease	7.71e-05	0.000493	CcSEcCtD
Doxorubicin—Asthenia—Montelukast—chronic obstructive pulmonary disease	7.67e-05	0.00049	CcSEcCtD
Doxorubicin—Abdominal distension—Prednisone—chronic obstructive pulmonary disease	7.61e-05	0.000486	CcSEcCtD
Doxorubicin—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	7.6e-05	0.000485	CcSEcCtD
Doxorubicin—Pruritus—Montelukast—chronic obstructive pulmonary disease	7.57e-05	0.000483	CcSEcCtD
Doxorubicin—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	7.47e-05	0.000477	CcSEcCtD
Doxorubicin—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	7.47e-05	0.000477	CcSEcCtD
Doxorubicin—Arrhythmia—Prednisolone—chronic obstructive pulmonary disease	7.44e-05	0.000475	CcSEcCtD
Doxorubicin—Pancreatitis—Prednisone—chronic obstructive pulmonary disease	7.41e-05	0.000473	CcSEcCtD
Doxorubicin—Asthenia—Salbutamol—chronic obstructive pulmonary disease	7.4e-05	0.000473	CcSEcCtD
Doxorubicin—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	7.32e-05	0.000468	CcSEcCtD
Doxorubicin—Pruritus—Salbutamol—chronic obstructive pulmonary disease	7.3e-05	0.000466	CcSEcCtD
Doxorubicin—Erythema—Prednisolone—chronic obstructive pulmonary disease	7.25e-05	0.000463	CcSEcCtD
Doxorubicin—Dizziness—Arformoterol—chronic obstructive pulmonary disease	7.22e-05	0.000461	CcSEcCtD
Doxorubicin—Dizziness—Formoterol—chronic obstructive pulmonary disease	7.22e-05	0.000461	CcSEcCtD
Doxorubicin—Dizziness—Montelukast—chronic obstructive pulmonary disease	7.07e-05	0.000452	CcSEcCtD
Doxorubicin—Neutropenia—Prednisone—chronic obstructive pulmonary disease	7.07e-05	0.000451	CcSEcCtD
Doxorubicin—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	7.05e-05	0.000451	CcSEcCtD
Doxorubicin—Vomiting—Arformoterol—chronic obstructive pulmonary disease	6.94e-05	0.000444	CcSEcCtD
Doxorubicin—Vomiting—Formoterol—chronic obstructive pulmonary disease	6.94e-05	0.000444	CcSEcCtD
Doxorubicin—Rash—Formoterol—chronic obstructive pulmonary disease	6.89e-05	0.00044	CcSEcCtD
Doxorubicin—Rash—Arformoterol—chronic obstructive pulmonary disease	6.89e-05	0.00044	CcSEcCtD
Doxorubicin—Dermatitis—Formoterol—chronic obstructive pulmonary disease	6.88e-05	0.00044	CcSEcCtD
Doxorubicin—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	6.88e-05	0.00044	CcSEcCtD
Doxorubicin—Weight increased—Prednisone—chronic obstructive pulmonary disease	6.88e-05	0.000439	CcSEcCtD
Doxorubicin—Headache—Formoterol—chronic obstructive pulmonary disease	6.84e-05	0.000437	CcSEcCtD
Doxorubicin—Headache—Arformoterol—chronic obstructive pulmonary disease	6.84e-05	0.000437	CcSEcCtD
Doxorubicin—Weight decreased—Prednisone—chronic obstructive pulmonary disease	6.84e-05	0.000437	CcSEcCtD
Doxorubicin—Vision blurred—Prednisolone—chronic obstructive pulmonary disease	6.83e-05	0.000436	CcSEcCtD
Doxorubicin—Dizziness—Salbutamol—chronic obstructive pulmonary disease	6.82e-05	0.000436	CcSEcCtD
Doxorubicin—Hyperglycaemia—Prednisone—chronic obstructive pulmonary disease	6.82e-05	0.000436	CcSEcCtD
Doxorubicin—Vomiting—Montelukast—chronic obstructive pulmonary disease	6.8e-05	0.000435	CcSEcCtD
Doxorubicin—Rash—Montelukast—chronic obstructive pulmonary disease	6.74e-05	0.000431	CcSEcCtD
Doxorubicin—Dermatitis—Montelukast—chronic obstructive pulmonary disease	6.74e-05	0.00043	CcSEcCtD
Doxorubicin—Ill-defined disorder—Prednisolone—chronic obstructive pulmonary disease	6.72e-05	0.00043	CcSEcCtD
Doxorubicin—Headache—Montelukast—chronic obstructive pulmonary disease	6.7e-05	0.000428	CcSEcCtD
Doxorubicin—Neuropathy peripheral—Prednisone—chronic obstructive pulmonary disease	6.6e-05	0.000422	CcSEcCtD
Doxorubicin—Vomiting—Salbutamol—chronic obstructive pulmonary disease	6.56e-05	0.000419	CcSEcCtD
Doxorubicin—Malaise—Prednisolone—chronic obstructive pulmonary disease	6.53e-05	0.000418	CcSEcCtD
Doxorubicin—Vertigo—Prednisolone—chronic obstructive pulmonary disease	6.51e-05	0.000416	CcSEcCtD
Doxorubicin—Rash—Salbutamol—chronic obstructive pulmonary disease	6.5e-05	0.000415	CcSEcCtD
Doxorubicin—Syncope—Prednisolone—chronic obstructive pulmonary disease	6.5e-05	0.000415	CcSEcCtD
Doxorubicin—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	6.5e-05	0.000415	CcSEcCtD
Doxorubicin—Nausea—Formoterol—chronic obstructive pulmonary disease	6.49e-05	0.000414	CcSEcCtD
Doxorubicin—Nausea—Arformoterol—chronic obstructive pulmonary disease	6.49e-05	0.000414	CcSEcCtD
Doxorubicin—Headache—Salbutamol—chronic obstructive pulmonary disease	6.46e-05	0.000413	CcSEcCtD
Doxorubicin—Loss of consciousness—Prednisolone—chronic obstructive pulmonary disease	6.37e-05	0.000407	CcSEcCtD
Doxorubicin—Nausea—Montelukast—chronic obstructive pulmonary disease	6.35e-05	0.000406	CcSEcCtD
Doxorubicin—Convulsion—Prednisolone—chronic obstructive pulmonary disease	6.28e-05	0.000401	CcSEcCtD
Doxorubicin—Hypertension—Prednisolone—chronic obstructive pulmonary disease	6.26e-05	0.0004	CcSEcCtD
Doxorubicin—Bradycardia—Prednisone—chronic obstructive pulmonary disease	6.16e-05	0.000393	CcSEcCtD
Doxorubicin—Nausea—Salbutamol—chronic obstructive pulmonary disease	6.12e-05	0.000391	CcSEcCtD
Doxorubicin—Discomfort—Prednisolone—chronic obstructive pulmonary disease	6.1e-05	0.000389	CcSEcCtD
Doxorubicin—Haemoglobin—Prednisone—chronic obstructive pulmonary disease	6.08e-05	0.000388	CcSEcCtD
Doxorubicin—Haemorrhage—Prednisone—chronic obstructive pulmonary disease	6.05e-05	0.000386	CcSEcCtD
Doxorubicin—TOP2A—Methyltestosterone—Prednisone—chronic obstructive pulmonary disease	5.96e-05	0.0229	CbGdCrCtD
Doxorubicin—Connective tissue disorder—Prednisone—chronic obstructive pulmonary disease	5.94e-05	0.00038	CcSEcCtD
Doxorubicin—Anaphylactic shock—Prednisolone—chronic obstructive pulmonary disease	5.91e-05	0.000378	CcSEcCtD
Doxorubicin—Oedema—Prednisolone—chronic obstructive pulmonary disease	5.91e-05	0.000378	CcSEcCtD
Doxorubicin—Shock—Prednisolone—chronic obstructive pulmonary disease	5.82e-05	0.000372	CcSEcCtD
Doxorubicin—TOP2A—Methyltestosterone—Prednisolone—chronic obstructive pulmonary disease	5.81e-05	0.0223	CbGdCrCtD
Doxorubicin—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	5.77e-05	0.000369	CcSEcCtD
Doxorubicin—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	5.72e-05	0.000365	CcSEcCtD
Doxorubicin—Eye disorder—Prednisone—chronic obstructive pulmonary disease	5.65e-05	0.000361	CcSEcCtD
Doxorubicin—Flushing—Prednisone—chronic obstructive pulmonary disease	5.61e-05	0.000359	CcSEcCtD
Doxorubicin—Angiopathy—Prednisone—chronic obstructive pulmonary disease	5.49e-05	0.000351	CcSEcCtD
Doxorubicin—Immune system disorder—Prednisone—chronic obstructive pulmonary disease	5.46e-05	0.000349	CcSEcCtD
Doxorubicin—Arrhythmia—Prednisone—chronic obstructive pulmonary disease	5.4e-05	0.000345	CcSEcCtD
Doxorubicin—Insomnia—Prednisolone—chronic obstructive pulmonary disease	5.35e-05	0.000342	CcSEcCtD
Doxorubicin—Alopecia—Prednisone—chronic obstructive pulmonary disease	5.35e-05	0.000342	CcSEcCtD
Doxorubicin—Paraesthesia—Prednisolone—chronic obstructive pulmonary disease	5.31e-05	0.000339	CcSEcCtD
Doxorubicin—Mental disorder—Prednisone—chronic obstructive pulmonary disease	5.3e-05	0.000339	CcSEcCtD
Doxorubicin—Erythema—Prednisone—chronic obstructive pulmonary disease	5.27e-05	0.000336	CcSEcCtD
Doxorubicin—Malnutrition—Prednisone—chronic obstructive pulmonary disease	5.27e-05	0.000336	CcSEcCtD
Doxorubicin—Pain—Prednisolone—chronic obstructive pulmonary disease	5.06e-05	0.000323	CcSEcCtD
Doxorubicin—Vision blurred—Prednisone—chronic obstructive pulmonary disease	4.96e-05	0.000317	CcSEcCtD
Doxorubicin—Ill-defined disorder—Prednisone—chronic obstructive pulmonary disease	4.89e-05	0.000312	CcSEcCtD
Doxorubicin—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	4.87e-05	0.000311	CcSEcCtD
Doxorubicin—Anaemia—Prednisone—chronic obstructive pulmonary disease	4.87e-05	0.000311	CcSEcCtD
Doxorubicin—Agitation—Prednisone—chronic obstructive pulmonary disease	4.84e-05	0.000309	CcSEcCtD
Doxorubicin—Malaise—Prednisone—chronic obstructive pulmonary disease	4.75e-05	0.000303	CcSEcCtD
Doxorubicin—Vertigo—Prednisone—chronic obstructive pulmonary disease	4.73e-05	0.000302	CcSEcCtD
Doxorubicin—Syncope—Prednisone—chronic obstructive pulmonary disease	4.72e-05	0.000302	CcSEcCtD
Doxorubicin—Urticaria—Prednisolone—chronic obstructive pulmonary disease	4.7e-05	0.0003	CcSEcCtD
Doxorubicin—Loss of consciousness—Prednisone—chronic obstructive pulmonary disease	4.63e-05	0.000296	CcSEcCtD
Doxorubicin—Convulsion—Prednisone—chronic obstructive pulmonary disease	4.56e-05	0.000291	CcSEcCtD
Doxorubicin—Hypertension—Prednisone—chronic obstructive pulmonary disease	4.55e-05	0.00029	CcSEcCtD
Doxorubicin—Arthralgia—Prednisone—chronic obstructive pulmonary disease	4.48e-05	0.000286	CcSEcCtD
Doxorubicin—Myalgia—Prednisone—chronic obstructive pulmonary disease	4.48e-05	0.000286	CcSEcCtD
Doxorubicin—Anxiety—Prednisone—chronic obstructive pulmonary disease	4.47e-05	0.000285	CcSEcCtD
Doxorubicin—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	4.45e-05	0.000284	CcSEcCtD
Doxorubicin—Discomfort—Prednisone—chronic obstructive pulmonary disease	4.43e-05	0.000283	CcSEcCtD
Doxorubicin—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	4.36e-05	0.000278	CcSEcCtD
Doxorubicin—Anaphylactic shock—Prednisone—chronic obstructive pulmonary disease	4.3e-05	0.000275	CcSEcCtD
Doxorubicin—Oedema—Prednisone—chronic obstructive pulmonary disease	4.3e-05	0.000275	CcSEcCtD
Doxorubicin—Infection—Prednisone—chronic obstructive pulmonary disease	4.27e-05	0.000273	CcSEcCtD
Doxorubicin—Shock—Prednisone—chronic obstructive pulmonary disease	4.23e-05	0.00027	CcSEcCtD
Doxorubicin—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	4.21e-05	0.000269	CcSEcCtD
Doxorubicin—Tachycardia—Prednisone—chronic obstructive pulmonary disease	4.19e-05	0.000268	CcSEcCtD
Doxorubicin—Skin disorder—Prednisone—chronic obstructive pulmonary disease	4.17e-05	0.000267	CcSEcCtD
Doxorubicin—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	4.15e-05	0.000265	CcSEcCtD
Doxorubicin—Anorexia—Prednisone—chronic obstructive pulmonary disease	4.1e-05	0.000262	CcSEcCtD
Doxorubicin—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	3.92e-05	0.00025	CcSEcCtD
Doxorubicin—Dizziness—Prednisolone—chronic obstructive pulmonary disease	3.91e-05	0.00025	CcSEcCtD
Doxorubicin—Insomnia—Prednisone—chronic obstructive pulmonary disease	3.89e-05	0.000248	CcSEcCtD
Doxorubicin—Paraesthesia—Prednisone—chronic obstructive pulmonary disease	3.86e-05	0.000247	CcSEcCtD
Doxorubicin—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	3.78e-05	0.000242	CcSEcCtD
Doxorubicin—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	3.74e-05	0.000239	CcSEcCtD
Doxorubicin—Rash—Prednisolone—chronic obstructive pulmonary disease	3.73e-05	0.000238	CcSEcCtD
Doxorubicin—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	3.73e-05	0.000238	CcSEcCtD
Doxorubicin—Fatigue—Prednisone—chronic obstructive pulmonary disease	3.71e-05	0.000237	CcSEcCtD
Doxorubicin—Headache—Prednisolone—chronic obstructive pulmonary disease	3.7e-05	0.000237	CcSEcCtD
Doxorubicin—Constipation—Prednisone—chronic obstructive pulmonary disease	3.67e-05	0.000235	CcSEcCtD
Doxorubicin—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	3.54e-05	0.000226	CcSEcCtD
Doxorubicin—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	3.51e-05	0.000225	CcSEcCtD
Doxorubicin—Nausea—Prednisolone—chronic obstructive pulmonary disease	3.51e-05	0.000224	CcSEcCtD
Doxorubicin—Urticaria—Prednisone—chronic obstructive pulmonary disease	3.41e-05	0.000218	CcSEcCtD
Doxorubicin—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	3.4e-05	0.000217	CcSEcCtD
Doxorubicin—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	3.4e-05	0.000217	CcSEcCtD
Doxorubicin—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	3.17e-05	0.000202	CcSEcCtD
Doxorubicin—Asthenia—Prednisone—chronic obstructive pulmonary disease	3.08e-05	0.000197	CcSEcCtD
Doxorubicin—Pruritus—Prednisone—chronic obstructive pulmonary disease	3.04e-05	0.000194	CcSEcCtD
Doxorubicin—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	2.94e-05	0.000188	CcSEcCtD
Doxorubicin—Dizziness—Prednisone—chronic obstructive pulmonary disease	2.84e-05	0.000182	CcSEcCtD
Doxorubicin—Vomiting—Prednisone—chronic obstructive pulmonary disease	2.73e-05	0.000175	CcSEcCtD
Doxorubicin—Rash—Prednisone—chronic obstructive pulmonary disease	2.71e-05	0.000173	CcSEcCtD
Doxorubicin—Dermatitis—Prednisone—chronic obstructive pulmonary disease	2.71e-05	0.000173	CcSEcCtD
Doxorubicin—Headache—Prednisone—chronic obstructive pulmonary disease	2.69e-05	0.000172	CcSEcCtD
Doxorubicin—Nausea—Prednisone—chronic obstructive pulmonary disease	2.55e-05	0.000163	CcSEcCtD
Doxorubicin—XDH—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.66e-05	0.00014	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.66e-05	0.00014	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—CTGF—chronic obstructive pulmonary disease	1.64e-05	0.000138	CbGpPWpGaD
Doxorubicin—NOS2—Disease—ERBB3—chronic obstructive pulmonary disease	1.64e-05	0.000138	CbGpPWpGaD
Doxorubicin—NOS1—Hemostasis—TP53—chronic obstructive pulmonary disease	1.64e-05	0.000138	CbGpPWpGaD
Doxorubicin—ABCC2—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	1.64e-05	0.000138	CbGpPWpGaD
Doxorubicin—NOS2—Hemostasis—VEGFA—chronic obstructive pulmonary disease	1.63e-05	0.000138	CbGpPWpGaD
Doxorubicin—ABCB1—Allograft Rejection—VEGFA—chronic obstructive pulmonary disease	1.62e-05	0.000137	CbGpPWpGaD
Doxorubicin—ABCC1—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	1.62e-05	0.000136	CbGpPWpGaD
Doxorubicin—TOP2A—Circadian rythm related genes—IL6—chronic obstructive pulmonary disease	1.62e-05	0.000136	CbGpPWpGaD
Doxorubicin—DHCR7—Metabolism—NOS3—chronic obstructive pulmonary disease	1.61e-05	0.000136	CbGpPWpGaD
Doxorubicin—CYP3A4—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	1.58e-05	0.000133	CbGpPWpGaD
Doxorubicin—CBR1—Metabolism—ALB—chronic obstructive pulmonary disease	1.57e-05	0.000132	CbGpPWpGaD
Doxorubicin—CYP3A4—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	1.56e-05	0.000131	CbGpPWpGaD
Doxorubicin—NQO1—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.55e-05	0.00013	CbGpPWpGaD
Doxorubicin—NQO1—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.52e-05	0.000128	CbGpPWpGaD
Doxorubicin—NOS1—Disease—SERPINE1—chronic obstructive pulmonary disease	1.52e-05	0.000128	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	1.51e-05	0.000127	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.51e-05	0.000127	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—ERBB3—chronic obstructive pulmonary disease	1.51e-05	0.000127	CbGpPWpGaD
Doxorubicin—AURKA—Cell Cycle—TP53—chronic obstructive pulmonary disease	1.5e-05	0.000127	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	1.5e-05	0.000127	CbGpPWpGaD
Doxorubicin—CBR1—Metabolism—NOS3—chronic obstructive pulmonary disease	1.5e-05	0.000126	CbGpPWpGaD
Doxorubicin—NOS2—Hemostasis—TGFB1—chronic obstructive pulmonary disease	1.5e-05	0.000126	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—APIP—chronic obstructive pulmonary disease	1.5e-05	0.000126	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.49e-05	0.000126	CbGpPWpGaD
Doxorubicin—ABCB1—Allograft Rejection—TGFB1—chronic obstructive pulmonary disease	1.49e-05	0.000126	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.47e-05	0.000124	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.47e-05	0.000124	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—GCLC—chronic obstructive pulmonary disease	1.46e-05	0.000123	CbGpPWpGaD
Doxorubicin—NOS1—Disease—NOS3—chronic obstructive pulmonary disease	1.46e-05	0.000123	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	1.45e-05	0.000122	CbGpPWpGaD
Doxorubicin—ABCG2—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	1.42e-05	0.00012	CbGpPWpGaD
Doxorubicin—NQO1—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.42e-05	0.00012	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.41e-05	0.000119	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—APIP—chronic obstructive pulmonary disease	1.41e-05	0.000119	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.41e-05	0.000118	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—GCLC—chronic obstructive pulmonary disease	1.4e-05	0.000118	CbGpPWpGaD
Doxorubicin—ABCB1—Allograft Rejection—TNF—chronic obstructive pulmonary disease	1.39e-05	0.000117	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.39e-05	0.000117	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.37e-05	0.000115	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.37e-05	0.000115	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	1.36e-05	0.000115	CbGpPWpGaD
Doxorubicin—NQO1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.35e-05	0.000113	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.34e-05	0.000113	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	1.34e-05	0.000113	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—CTGF—chronic obstructive pulmonary disease	1.33e-05	0.000112	CbGpPWpGaD
Doxorubicin—CYP3A4—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	1.32e-05	0.000111	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—GC—chronic obstructive pulmonary disease	1.31e-05	0.00011	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	1.3e-05	0.00011	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.3e-05	0.000109	CbGpPWpGaD
Doxorubicin—CYP3A4—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	1.3e-05	0.000109	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.3e-05	0.000109	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	1.28e-05	0.000108	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—CTGF—chronic obstructive pulmonary disease	1.28e-05	0.000107	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	1.27e-05	0.000107	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.27e-05	0.000107	CbGpPWpGaD
Doxorubicin—NOS3—Disease—ERBB3—chronic obstructive pulmonary disease	1.27e-05	0.000107	CbGpPWpGaD
Doxorubicin—NOS3—Hemostasis—VEGFA—chronic obstructive pulmonary disease	1.27e-05	0.000107	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.26e-05	0.000106	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—NOS2—chronic obstructive pulmonary disease	1.25e-05	0.000106	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.24e-05	0.000105	CbGpPWpGaD
Doxorubicin—ABCC3—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	1.24e-05	0.000104	CbGpPWpGaD
Doxorubicin—NOS2—Hemostasis—TP53—chronic obstructive pulmonary disease	1.23e-05	0.000104	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.23e-05	0.000103	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.22e-05	0.000102	CbGpPWpGaD
Doxorubicin—CYP3A4—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	1.21e-05	0.000102	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.21e-05	0.000102	CbGpPWpGaD
Doxorubicin—CYP3A4—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	1.19e-05	0.000101	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.19e-05	0.0001	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.18e-05	9.9e-05	CbGpPWpGaD
Doxorubicin—NOS3—Hemostasis—TGFB1—chronic obstructive pulmonary disease	1.16e-05	9.81e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.16e-05	9.77e-05	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.16e-05	9.76e-05	CbGpPWpGaD
Doxorubicin—NOS2—Disease—SERPINE1—chronic obstructive pulmonary disease	1.15e-05	9.69e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	1.15e-05	9.66e-05	CbGpPWpGaD
Doxorubicin—YWHAG—Cell Cycle—TP53—chronic obstructive pulmonary disease	1.14e-05	9.59e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	1.13e-05	9.53e-05	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	1.13e-05	9.53e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—HDAC2—chronic obstructive pulmonary disease	1.11e-05	9.37e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.11e-05	9.34e-05	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.1e-05	9.25e-05	CbGpPWpGaD
Doxorubicin—NOS2—Disease—NOS3—chronic obstructive pulmonary disease	1.1e-05	9.25e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.1e-05	9.24e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—GCLC—chronic obstructive pulmonary disease	1.1e-05	9.23e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.07e-05	9.03e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—NOS2—chronic obstructive pulmonary disease	1.06e-05	8.93e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—GCLC—chronic obstructive pulmonary disease	1.06e-05	8.93e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—SERPINE1—chronic obstructive pulmonary disease	1.06e-05	8.9e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.05e-05	8.88e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—KL—chronic obstructive pulmonary disease	1.03e-05	8.71e-05	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	1.02e-05	8.62e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.02e-05	8.61e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	1.02e-05	8.6e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.01e-05	8.55e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—NOS3—chronic obstructive pulmonary disease	1.01e-05	8.5e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.01e-05	8.5e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—CTGF—chronic obstructive pulmonary disease	9.99e-06	8.42e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	9.92e-06	8.36e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	9.88e-06	8.32e-05	CbGpPWpGaD
Doxorubicin—ABCC2—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	9.82e-06	8.28e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—GSTP1—chronic obstructive pulmonary disease	9.8e-06	8.26e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	9.8e-06	8.26e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—GSTT1—chronic obstructive pulmonary disease	9.75e-06	8.21e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	9.71e-06	8.18e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—CTGF—chronic obstructive pulmonary disease	9.67e-06	8.14e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—HMOX1—chronic obstructive pulmonary disease	9.67e-06	8.14e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—GC—chronic obstructive pulmonary disease	9.65e-06	8.13e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—GCLC—chronic obstructive pulmonary disease	9.64e-06	8.12e-05	CbGpPWpGaD
Doxorubicin—NOS1—Disease—TGFB1—chronic obstructive pulmonary disease	9.62e-06	8.11e-05	CbGpPWpGaD
Doxorubicin—NOS3—Hemostasis—TP53—chronic obstructive pulmonary disease	9.59e-06	8.08e-05	CbGpPWpGaD
Doxorubicin—NOS1—Disease—EGFR—chronic obstructive pulmonary disease	9.44e-06	7.95e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—LEP—chronic obstructive pulmonary disease	9.43e-06	7.95e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—GSTM1—chronic obstructive pulmonary disease	9.39e-06	7.92e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	9.35e-06	7.88e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—APIP—chronic obstructive pulmonary disease	9.23e-06	7.77e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	9.21e-06	7.76e-05	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	9.19e-06	7.74e-05	CbGpPWpGaD
Doxorubicin—NQO1—Metabolism—ALB—chronic obstructive pulmonary disease	9.16e-06	7.71e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—GC—chronic obstructive pulmonary disease	9.09e-06	7.66e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—GSTM1—chronic obstructive pulmonary disease	9.01e-06	7.59e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	8.97e-06	7.56e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—SERPINE1—chronic obstructive pulmonary disease	8.93e-06	7.52e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—CYP1A1—chronic obstructive pulmonary disease	8.91e-06	7.5e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	8.91e-06	7.5e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	8.91e-06	7.5e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism—ALB—chronic obstructive pulmonary disease	8.83e-06	7.44e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—CTGF—chronic obstructive pulmonary disease	8.79e-06	7.41e-05	CbGpPWpGaD
Doxorubicin—NQO1—Metabolism—NOS3—chronic obstructive pulmonary disease	8.76e-06	7.38e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	8.57e-06	7.22e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	8.54e-06	7.2e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—CYP1A1—chronic obstructive pulmonary disease	8.54e-06	7.19e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	8.45e-06	7.12e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism—NOS3—chronic obstructive pulmonary disease	8.45e-06	7.12e-05	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	8.43e-06	7.1e-05	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	8.27e-06	6.96e-05	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—ALB—chronic obstructive pulmonary disease	8.21e-06	6.92e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—CYP1A2—chronic obstructive pulmonary disease	8.1e-06	6.83e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—chronic obstructive pulmonary disease	8.02e-06	6.76e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—LEP—chronic obstructive pulmonary disease	7.97e-06	6.71e-05	CbGpPWpGaD
Doxorubicin—TOP2A—Cell Cycle—TP53—chronic obstructive pulmonary disease	7.96e-06	6.71e-05	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—NOS3—chronic obstructive pulmonary disease	7.85e-06	6.62e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—ERBB3—chronic obstructive pulmonary disease	7.75e-06	6.53e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	7.69e-06	6.48e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—GSTP1—chronic obstructive pulmonary disease	7.68e-06	6.47e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—HMOX1—chronic obstructive pulmonary disease	7.57e-06	6.38e-05	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—ALB—chronic obstructive pulmonary disease	7.46e-06	6.29e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—GSTP1—chronic obstructive pulmonary disease	7.43e-06	6.26e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	7.4e-06	6.24e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—chronic obstructive pulmonary disease	7.36e-06	6.2e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—HMOX1—chronic obstructive pulmonary disease	7.33e-06	6.17e-05	CbGpPWpGaD
Doxorubicin—NOS2—Disease—TGFB1—chronic obstructive pulmonary disease	7.26e-06	6.12e-05	CbGpPWpGaD
Doxorubicin—NOS1—Disease—IL6—chronic obstructive pulmonary disease	7.25e-06	6.11e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—chronic obstructive pulmonary disease	7.22e-06	6.08e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—GSTT1—chronic obstructive pulmonary disease	7.15e-06	6.02e-05	CbGpPWpGaD
Doxorubicin—NOS2—Disease—EGFR—chronic obstructive pulmonary disease	7.12e-06	6e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	7.06e-06	5.95e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—GCLC—chronic obstructive pulmonary disease	7.06e-06	5.95e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—GSTM1—chronic obstructive pulmonary disease	7.06e-06	5.95e-05	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	6.94e-06	5.85e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—chronic obstructive pulmonary disease	6.87e-06	5.79e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—GSTM1—chronic obstructive pulmonary disease	6.83e-06	5.75e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—GSTP1—chronic obstructive pulmonary disease	6.76e-06	5.69e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	6.69e-06	5.64e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—TGFB1—chronic obstructive pulmonary disease	6.67e-06	5.62e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—HMOX1—chronic obstructive pulmonary disease	6.66e-06	5.62e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—EGFR—chronic obstructive pulmonary disease	6.54e-06	5.51e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	6.47e-06	5.45e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—NOS2—chronic obstructive pulmonary disease	6.46e-06	5.44e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—CTGF—chronic obstructive pulmonary disease	6.45e-06	5.43e-05	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	6.35e-06	5.35e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	6.27e-06	5.28e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	6.25e-06	5.27e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—GSTM1—chronic obstructive pulmonary disease	6.21e-06	5.23e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	6.11e-06	5.15e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—chronic obstructive pulmonary disease	6.06e-06	5.1e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—ALB—chronic obstructive pulmonary disease	6.05e-06	5.1e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—GC—chronic obstructive pulmonary disease	5.94e-06	5.01e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—CYP1A2—chronic obstructive pulmonary disease	5.94e-06	5e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—CYP1A1—chronic obstructive pulmonary disease	5.89e-06	4.96e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—ALB—chronic obstructive pulmonary disease	5.8e-06	4.89e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—NOS3—chronic obstructive pulmonary disease	5.79e-06	4.88e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	5.67e-06	4.78e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—TGFB1—chronic obstructive pulmonary disease	5.64e-06	4.75e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—NOS3—chronic obstructive pulmonary disease	5.55e-06	4.68e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—EGFR—chronic obstructive pulmonary disease	5.53e-06	4.66e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	5.53e-06	4.66e-05	CbGpPWpGaD
Doxorubicin—NOS2—Disease—IL6—chronic obstructive pulmonary disease	5.47e-06	4.61e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—SERPINE1—chronic obstructive pulmonary disease	5.44e-06	4.58e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	5.3e-06	4.46e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—GSTT1—chronic obstructive pulmonary disease	5.27e-06	4.44e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—GCLC—chronic obstructive pulmonary disease	5.21e-06	4.39e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—NOS3—chronic obstructive pulmonary disease	5.19e-06	4.38e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	5.09e-06	4.29e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—IL6—chronic obstructive pulmonary disease	5.03e-06	4.24e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—GSTT1—chronic obstructive pulmonary disease	4.97e-06	4.19e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—GSTP1—chronic obstructive pulmonary disease	4.95e-06	4.17e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—GCLC—chronic obstructive pulmonary disease	4.91e-06	4.14e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—HMOX1—chronic obstructive pulmonary disease	4.89e-06	4.12e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	4.79e-06	4.04e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—CTGF—chronic obstructive pulmonary disease	4.75e-06	4.01e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	4.67e-06	3.94e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	4.62e-06	3.89e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	4.58e-06	3.86e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—GSTM1—chronic obstructive pulmonary disease	4.55e-06	3.84e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—ALB—chronic obstructive pulmonary disease	4.55e-06	3.83e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—CTGF—chronic obstructive pulmonary disease	4.48e-06	3.78e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—ALB—chronic obstructive pulmonary disease	4.4e-06	3.71e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	4.38e-06	3.69e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—NOS3—chronic obstructive pulmonary disease	4.35e-06	3.67e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—CYP1A1—chronic obstructive pulmonary disease	4.32e-06	3.64e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	4.3e-06	3.62e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—IL6—chronic obstructive pulmonary disease	4.25e-06	3.58e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—NOS3—chronic obstructive pulmonary disease	4.21e-06	3.55e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—CYP1A2—chronic obstructive pulmonary disease	4.13e-06	3.48e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—ALB—chronic obstructive pulmonary disease	4e-06	3.37e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	3.95e-06	3.33e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	3.87e-06	3.26e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—TP53—chronic obstructive pulmonary disease	3.85e-06	3.24e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—NOS3—chronic obstructive pulmonary disease	3.83e-06	3.23e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—GSTP1—chronic obstructive pulmonary disease	3.65e-06	3.08e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—HMOX1—chronic obstructive pulmonary disease	3.6e-06	3.04e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.52e-06	2.97e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—GSTP1—chronic obstructive pulmonary disease	3.44e-06	2.9e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—TGFB1—chronic obstructive pulmonary disease	3.43e-06	2.89e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—HMOX1—chronic obstructive pulmonary disease	3.4e-06	2.86e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—EGFR—chronic obstructive pulmonary disease	3.37e-06	2.84e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—GSTM1—chronic obstructive pulmonary disease	3.36e-06	2.83e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—TP53—chronic obstructive pulmonary disease	3.25e-06	2.74e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—GSTT1—chronic obstructive pulmonary disease	3.25e-06	2.74e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—GCLC—chronic obstructive pulmonary disease	3.21e-06	2.7e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	3.18e-06	2.68e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—GSTM1—chronic obstructive pulmonary disease	3.16e-06	2.67e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—CYP1A1—chronic obstructive pulmonary disease	3e-06	2.53e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.97e-06	2.51e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—ALB—chronic obstructive pulmonary disease	2.93e-06	2.47e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—CTGF—chronic obstructive pulmonary disease	2.93e-06	2.47e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—NOS3—chronic obstructive pulmonary disease	2.81e-06	2.36e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	2.7e-06	2.27e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—IL6—chronic obstructive pulmonary disease	2.59e-06	2.18e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—GSTP1—chronic obstructive pulmonary disease	2.25e-06	1.9e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—HMOX1—chronic obstructive pulmonary disease	2.22e-06	1.87e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—ALB—chronic obstructive pulmonary disease	2.16e-06	1.82e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—NOS3—chronic obstructive pulmonary disease	2.07e-06	1.74e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—GSTM1—chronic obstructive pulmonary disease	2.07e-06	1.74e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—ALB—chronic obstructive pulmonary disease	2.04e-06	1.72e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.96e-06	1.65e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—NOS3—chronic obstructive pulmonary disease	1.95e-06	1.64e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—ALB—chronic obstructive pulmonary disease	1.33e-06	1.12e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—NOS3—chronic obstructive pulmonary disease	1.28e-06	1.07e-05	CbGpPWpGaD
